Press Releases

MYOS RENS to Introduce the Qurr® Line of Muscle Health Products at 35th IDEA World Convention July 19-23, 2017 in Las Vegas

Download PDF

Over 10,000 Fitness, Wellness, Nutrition, Business and Mind-Body Professionals Will Be In Attendance As MYOS RENS Rolls Out Its 90-Day Qurr® Challenge

CEDAR KNOLLS, N.J., July 12, 2017 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), announced today that it will be a sponsor at this year's IDEA World Convention in Las Vegas to "put its money where its mouth is" with a 90-day money back guarantee on their Qurr Fortetopin® line of muscle health products.  MYOS is assuring customers that they will see results in 90 days using Qurr Fortetropin® powders or shakes in conjunction with resistance training– or they can get their money back.

"We are pleased to be a sponsor at the IDEA World Convention, which has set the standard for the fitness/wellness industry for over 35 years," said Joseph Mannello, CEO.  IDEA provides education, program evaluation, trends and research to a 250,000-member data base of credentialed trainers, program/fitness directors, business owners, and nutrition professionals. "This is an excellent venue for MYOS to introduce Qurr Fortetropin® to the professional wellness and fitness community," Mr. Mannello continued.   Qurr Fortetropin® is MYOS' proprietary ingredient that naturally reduces myostatin and which has been clinically shown to build lean muscle mass and improve muscle function.

The 90-Day Qurr® Challenge guarantee is simple:  the consumer takes the product daily for 90 days in conjunction with resistance training twice per week, and should be able to observe improvements in muscle health (this could translate into more muscle definition, being more toned, or gains in strength).  If not satisfied, the consumer should send us before-and-after pictures with a brief description of their experience while on the product.  If the consumer follows these instructions and does not get the benefit(s) described, MYOS will refund the full purchase price (details:

The Qurr® line of muscle health products will be on display in Booth #1841 at the Las Vegas IDEA World Convention July 19-23.

About MYOS RENS Technology Inc.
MYOS RENS Technology (MYOS), "The Muscle Company™", is a Cedar Knolls, NJ-based biotherapeutics and bionutrition company focused on developing products that improve muscle health and performance and bringing them to market. MYOS is the owner of Fortetropin®, the world's first clinically demonstrated myostatin reducer. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Fortetropin® is manufactured to optimize biological activity, which MYOS believes has the potential to redefine existing standards of physical health and wellness enhancement.

Forward-Looking Statements 
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful launch of our products, including Qurr® products, the success of our research and development, the results of the clinical evaluation of Fortetropin® and its effects, the ability to enter into partnership opportunities, the ability to generate the forecasted revenue stream and cash flow from sales of our products, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

Media Contact
MYOS RENS Technology Inc.
Joanne Goodford


View original content with multimedia: